| Artificially cloaked viral nanovaccine for cancer immunotherapy M Fusciello, F Fontana, S Tähtinen, C Capasso, S Feola, B Martins, ... Nature Communications 10 (1), 5747, 2019 | 107 | 2019 |
| Exploiting preexisting immunity to enhance oncolytic cancer immunotherapy S Tähtinen, S Feola, C Capasso, N Laustio, C Groeneveldt, EO Ylösmäki, ... Cancer Research 80 (12), 2575-2585, 2020 | 44 | 2020 |
| Biohybrid vaccines for improved treatment of aggressive melanoma with checkpoint inhibitor F Fontana, M Fusciello, C Groeneveldt, C Capasso, J Chiaro, S Feola, ... ACS nano 13 (6), 6477-6490, 2019 | 41 | 2019 |
| Uncovering the tumor antigen landscape: what to know about the discovery process S Feola, J Chiaro, B Martins, V Cerullo Cancers 12 (6), 1660, 2020 | 39 | 2020 |
| Viral molecular mimicry influences the antitumor immune response in murine and human melanoma J Chiaro, HHE Kasanen, T Whalley, C Capasso, M Grönholm, S Feola, ... Cancer immunology research 9 (8), 981-993, 2021 | 29 | 2021 |
| Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro … F Hamdan, E Ylösmäki, J Chiaro, Y Giannoula, M Long, M Fusciello, ... Journal for Immunotherapy of Cancer 9 (8), 2021 | 26 | 2021 |
| A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines S Feola, J Chiaro, B Martins, S Russo, M Fusciello, E Ylösmäki, C Bonini, ... Elife 11, e71156, 2022 | 25 | 2022 |
| Influence of cell membrane wrapping on the Cell− porous silicon nanoparticle interactions F Fontana, H Lindstedt, A Correia, J Chiaro, OK Kari, J Ndika, H Alenius, ... Advanced healthcare materials 9 (17), 2000529, 2020 | 20 | 2020 |
| Surfaceome and Exoproteome Dynamics in Dual-Species Pseudomonas aeruginosa and Staphylococcus aureus Biofilms I Reigada, P San-Martin-Galindo, S Gilbert-Girard, J Chiaro, V Cerullo, ... Frontiers in Microbiology 12, 672975, 2021 | 17 | 2021 |
| Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin E Ylösmäki, M Fusciello, B Martins, S Feola, F Hamdan, J Chiaro, ... Journal for Immunotherapy of Cancer 9 (7), 2021 | 17 | 2021 |
| PeptiCHIP: a microfluidic platform for tumor antigen landscape identification S Feola, M Haapala, K Peltonen, C Capasso, B Martins, G Antignani, ... ACS nano 15 (10), 15992-16010, 2021 | 15 | 2021 |
| Therapeutic cancer vaccination with immunopeptidomics-discovered antigens confers protective antitumor efficacy K Peltonen, S Feola, HM Umer, J Chiaro, G Mermelekas, E Ylösmäki, ... Cancers 13 (14), 3408, 2021 | 14 | 2021 |
| Peptides-coated oncolytic vaccines for cancer personalized medicine S Feola, S Russo, B Martins, A Lopes, G Vandermeulen, V Fluhler, ... Frontiers in Immunology 13, 826164, 2022 | 12 | 2022 |
| GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses F Hamdan, B Martins, M Feodoroff, Y Giannoula, S Feola, M Fusciello, ... Molecular Therapy-Methods & Clinical Development 20, 625-634, 2021 | 8 | 2021 |
| A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella M Fusciello, E Ylösmäki, S Feola, A Uoti, B Martins, K Aalto, F Hamdan, ... Molecular Therapy-Oncolytics 25, 137-145, 2022 | 6 | 2022 |
| Integrating immunopeptidome analysis for the design and development of cancer vaccines S Feola, J Chiaro, V Cerullo Seminars in immunology 67, 101750, 2023 | 2 | 2023 |
| Cell Membrane Wrapping: Influence of Cell Membrane Wrapping on the Cell− Porous Silicon Nanoparticle Interactions (Adv. Healthcare Mater. 17/2020) F Fontana, H Lindstedt, A Correia, J Chiaro, OK Kari, J Ndika, H Alenius, ... Advanced Healthcare Materials 9 (17), 2070056, 2020 | 2 | 2020 |
| Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors J Chiaro, G Antignani, S Feola, M Feodoroff, B Martins, H Cojoc, S Russo, ... Nature Communications 14 (1), 7056, 2023 | 1 | 2023 |
| Controlled release of enhanced cross-hybrid IgGA Fc PD-L1 inhibitors using oncolytic adenoviruses F Hamdan, M Feodoroff, S Russo, M Fusciello, S Feola, J Chiaro, ... Molecular Therapy-Oncolytics 28, 264-276, 2023 | 1 | 2023 |
| Development of mesothelioma-specific oncolytic vaccine exploiting immunopeptidomic analysis of murine and human tumors J Chiaro, G Antignani, S Feola, M Feodoroff, B Martins, H Cojoc, V Ferrari, ... | 1 | 2022 |
